BR112017008160A2 - peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição. - Google Patents
peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição.Info
- Publication number
- BR112017008160A2 BR112017008160A2 BR112017008160A BR112017008160A BR112017008160A2 BR 112017008160 A2 BR112017008160 A2 BR 112017008160A2 BR 112017008160 A BR112017008160 A BR 112017008160A BR 112017008160 A BR112017008160 A BR 112017008160A BR 112017008160 A2 BR112017008160 A2 BR 112017008160A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- treating
- composition
- receptor
- glucagon
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 208000016097 disease of metabolism Diseases 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 108010011903 peptide receptors Proteins 0.000 abstract 1
- 102000014187 peptide receptors Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
são descritos análogos de peptídeo de glucagon, que foram modificados para serem resistentes à clivagem e à inatividade pela dipeptidil peptidase iv (dpp-iv) e para aumentarem in vivo a meia-vida do análogo de peptídeo enquanto permitem que o análogo de peptídeo tenha atividade agonista relativamente equilibrada no receptor de peptídeo tipo glucagon 1 (glp-1) e no receptor de glucagon (gcg), e o uso de tais coagonistas de receptor de glp-1/receptor de gcg para tratamento de distúrbios metabólicos, tais como diabetes, doença hepática gordurosa não alcoólica (dhgna), esteatohepatite não alcoólica (nash) e obesidade.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068157P | 2014-10-24 | 2014-10-24 | |
| US201562208869P | 2015-08-24 | 2015-08-24 | |
| PCT/US2015/056794 WO2016065090A1 (en) | 2014-10-24 | 2015-10-22 | Co-agonists of the glucagon and glp-1 receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017008160A2 true BR112017008160A2 (pt) | 2018-03-06 |
| BR112017008160A8 BR112017008160A8 (pt) | 2023-04-11 |
Family
ID=54397022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008160A BR112017008160A8 (pt) | 2014-10-24 | 2015-10-22 | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10413593B2 (pt) |
| EP (2) | EP3209682B1 (pt) |
| JP (1) | JP6581656B2 (pt) |
| KR (1) | KR101996739B1 (pt) |
| CN (1) | CN107108715A (pt) |
| AU (1) | AU2015335828B2 (pt) |
| BR (1) | BR112017008160A8 (pt) |
| CA (2) | CA3093383A1 (pt) |
| CL (1) | CL2017000982A1 (pt) |
| CO (1) | CO2017003832A2 (pt) |
| CR (1) | CR20170164A (pt) |
| DO (1) | DOP2017000102A (pt) |
| EA (1) | EA201790914A1 (pt) |
| GT (1) | GT201700085A (pt) |
| IL (1) | IL251741A0 (pt) |
| MA (1) | MA55068A (pt) |
| MD (1) | MD20170055A2 (pt) |
| MX (1) | MX2017005280A (pt) |
| NI (1) | NI201700048A (pt) |
| PE (1) | PE20180158A1 (pt) |
| PH (1) | PH12017500761A1 (pt) |
| SG (1) | SG11201703238TA (pt) |
| SV (1) | SV2017005425A (pt) |
| TN (1) | TN2017000148A1 (pt) |
| TW (1) | TW201625672A (pt) |
| WO (1) | WO2016065090A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104870009B (zh) | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
| WO2015184177A1 (en) * | 2014-05-28 | 2015-12-03 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| MD20170055A2 (ro) | 2014-10-24 | 2017-09-30 | Merck Sharp & Dohme Corp | Co-agonişti ai receptorilor glucagonului şi GLP-1 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2017074798A2 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Long-acting co-agonists of the glucagon and glp-1 receptors |
| CA3072118A1 (en) * | 2017-08-09 | 2019-02-14 | Sanofi | Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
| KR102505628B1 (ko) * | 2017-09-25 | 2023-03-02 | 머크 샤프 앤드 돔 엘엘씨 | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 |
| CN114920818B (zh) * | 2017-11-06 | 2024-02-27 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
| EP3735295A1 (en) * | 2018-01-03 | 2020-11-11 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| MX2021003830A (es) * | 2018-10-04 | 2021-09-30 | Hanmi Pharm Ind Co Ltd | Uso terapéutico del glucagón y combinación que incluye el mismo. |
| CN111171135B (zh) * | 2018-11-12 | 2023-04-07 | 天津药物研究院有限公司 | 具有双重受体激动作用的胰高血糖素衍生肽及其用途 |
| CN113631568A (zh) * | 2019-02-06 | 2021-11-09 | 恩泽生物科学有限公司 | 胰高血糖素样肽-1(glp-1)激动剂类似物，其制备方法和用途 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| EP3842060A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled lactam co-agonists of the glucagon and glp-1 receptors |
| EP3842449A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| EP3842061A1 (en) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled triazole co-agonists of the glucagon and glp-1 receptors |
| US20230190879A1 (en) * | 2020-05-29 | 2023-06-22 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Dual-agonist compound for both glp-1 and gip receptors and application thereof |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
| WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
| CN112608378B (zh) * | 2020-12-09 | 2023-09-08 | 江苏师范大学 | 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用 |
| CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
| WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
| WO2024098718A1 (zh) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| DK0970095T3 (da) | 1997-03-07 | 2004-03-08 | Metabasis Therapeutics Inc | Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase |
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| AU761267C (en) | 1998-09-09 | 2007-08-09 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| CA2373892A1 (en) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| ATE424413T1 (de) * | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
| DE60128475T2 (de) | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
| WO2002060388A2 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| PT1441589E (pt) | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
| AU2003239478A1 (en) | 2002-06-04 | 2003-12-22 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| AU2003260085B2 (en) | 2002-08-29 | 2008-09-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2512879A1 (en) | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| US20090238820A1 (en) | 2005-03-08 | 2009-09-24 | Allan Corey M | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| EP1959986B1 (en) | 2005-11-07 | 2014-07-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2008010017A1 (en) | 2006-07-19 | 2008-01-24 | Freescale Semiconductor, Inc. | Method and apparatus for designing an integrated circuit |
| CN101553504A (zh) | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| SG177953A1 (en) | 2007-01-05 | 2012-02-28 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| US20090060906A1 (en) | 2007-01-09 | 2009-03-05 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| US20100144679A1 (en) | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
| JP2010531307A (ja) | 2007-06-28 | 2010-09-24 | メルク フロスト カナダ リミテツド | Ｇｐｒ１０５活性のアンタゴニストとしての置換縮合ピリミジン |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| CN102088989B (zh) | 2008-06-17 | 2014-11-26 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
| JP6108659B2 (ja) | 2008-06-17 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
| ES2534191T3 (es) * | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2788304A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| WO2011143208A1 (en) * | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| AR081434A1 (es) | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
| MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| WO2011163462A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| AU2011348202A1 (en) | 2010-12-22 | 2013-07-04 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides |
| WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| WO2012150503A2 (en) * | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| EP2723367B1 (en) | 2011-06-22 | 2017-05-03 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JP6184404B2 (ja) * | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプターコアゴニスト |
| WO2013003449A2 (en) * | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| ES2644313T3 (es) | 2011-08-02 | 2017-11-28 | Nano3D Biosciences, Inc. | Hardware para cultivo magnético en 3D |
| CA2877127A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
| BR112015017619A2 (pt) | 2013-01-24 | 2017-11-21 | Glaxosmithkline Ip Dev Ltd | formulação líquida, uso de uma formulação, e, kit |
| MD20170055A2 (ro) | 2014-10-24 | 2017-09-30 | Merck Sharp & Dohme Corp | Co-agonişti ai receptorilor glucagonului şi GLP-1 |
-
2015
- 2015-10-22 MD MDA20170055A patent/MD20170055A2/ro not_active Application Discontinuation
- 2015-10-22 AU AU2015335828A patent/AU2015335828B2/en active Active
- 2015-10-22 CA CA3093383A patent/CA3093383A1/en not_active Abandoned
- 2015-10-22 WO PCT/US2015/056794 patent/WO2016065090A1/en active Application Filing
- 2015-10-22 US US15/519,565 patent/US10413593B2/en active Active
- 2015-10-22 CN CN201580070222.3A patent/CN107108715A/zh active Pending
- 2015-10-22 MA MA055068A patent/MA55068A/fr unknown
- 2015-10-22 EP EP15790398.0A patent/EP3209682B1/en active Active
- 2015-10-22 CA CA2964379A patent/CA2964379C/en active Active
- 2015-10-22 SG SG11201703238TA patent/SG11201703238TA/en unknown
- 2015-10-22 KR KR1020177013556A patent/KR101996739B1/ko active IP Right Grant
- 2015-10-22 JP JP2017521548A patent/JP6581656B2/ja active Active
- 2015-10-22 EA EA201790914A patent/EA201790914A1/ru unknown
- 2015-10-22 EP EP20212705.6A patent/EP3825324A1/en active Pending
- 2015-10-22 TW TW104134741A patent/TW201625672A/zh unknown
- 2015-10-22 BR BR112017008160A patent/BR112017008160A8/pt active Search and Examination
- 2015-10-22 TN TN2017000148A patent/TN2017000148A1/en unknown
- 2015-10-22 CR CR20170164A patent/CR20170164A/es unknown
- 2015-10-22 US US14/920,012 patent/US20160114000A1/en not_active Abandoned
- 2015-10-22 MX MX2017005280A patent/MX2017005280A/es unknown
- 2015-10-22 PE PE2017001204A patent/PE20180158A1/es unknown
-
2017
- 2017-04-13 IL IL251741A patent/IL251741A0/en unknown
- 2017-04-20 CL CL2017000982A patent/CL2017000982A1/es unknown
- 2017-04-20 CO CONC2017/0003832A patent/CO2017003832A2/es unknown
- 2017-04-21 NI NI201700048A patent/NI201700048A/es unknown
- 2017-04-24 PH PH12017500761A patent/PH12017500761A1/en unknown
- 2017-04-24 DO DO2017000102A patent/DOP2017000102A/es unknown
- 2017-04-24 GT GT201700085A patent/GT201700085A/es unknown
- 2017-04-24 SV SV2017005425A patent/SV2017005425A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017008160A2 (pt) | peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição. | |
| PH12020551025A1 (en) | Incretin analogs and uses thereof | |
| PH12020551024A1 (en) | Incretin analogs and uses thereof | |
| CO2018000078A2 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| ECSP10010684A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad. | |
| PH12015500531A1 (en) | Glucagon analogues | |
| PH12016500675B1 (en) | Acylated glucagon analogues | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2016004907A (es) | Analogos del glucagon. | |
| CR20170129A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
| MX2017012864A (es) | Analogo acilado del glucagon. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2020011099A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| ECSP17032341A (es) | Coagonistas de los receptores de glucagón y de glp-1 | |
| RE | Nausea, chronic uveitis and elevated liver enzymes: 4 case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |